1-20 of 21
Bernard Escudier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade

Stéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, Julien Adam, Maxime Meylan, Stéphanie Buart, Antoine Bougoüin, Alexandra Lespagnol, Frédéric Dugay, Irelka Colina Moreno, Guillaume Lacroix, James B. Lorens, Gro Gausdal, Wolf H. Fridman, Fathia Mami-Chouaib, Nathalie Chaput, Benoit Beuselinck, Sylvie Chabaud, Janice Barros-Monteiro, Yann Vano, Bernard Escudier, Catherine Sautès-Fridman, Laurence Albiges, Salem Chouaib
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6749–6760.
https://doi.org/10.1158/1078-0432.CCR-21-0972
Published: 15 December 2021
View article titled, Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Open the PDF for Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade in another window
Includes: Supplementary data
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial

Anup Patel, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J. George
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4863–4868.
https://doi.org/10.1158/1078-0432.CCR-20-0704
Published: 15 September 2020
View article titled, Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
Open the PDF for Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial in another window
Journal Articles

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Michael B. Atkins, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, Carsten Grüllich, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piault-Louis, Christina Schiff, Bernard Escudier
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2506–2514.
https://doi.org/10.1158/1078-0432.CCR-19-2838
Published: 01 June 2020
View article titled, Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Open the PDF for Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Abdallah Flaifel, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, Bernard Escudier, Daniel J. George, Robert J. Motzer, Michael J. Morris, Thomas Powles, Evelyn Wang, Ying Huang, Gordon J. Freeman, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6080–6088.
https://doi.org/10.1158/1078-0432.CCR-19-1135
Published: 15 October 2019
View article titled, PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Open the PDF for PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN in another window
Includes: Supplementary data
Journal Articles

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Daniel J. George, Jean-Francois Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev S. Pandha, Anup Patel, Maria Lechuga, Alain Ravaud
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1165–1173.
https://doi.org/10.1158/1078-0432.CCR-18-1724
Published: 15 February 2019
View article titled, Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Open the PDF for Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis in another window
Includes: Supplementary data
Journal Articles

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib

Brian I. Rini, Bernard Escudier, Jean-Francois Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Phillip G. Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J. Motzer, Alain Ravaud
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4407–4415.
https://doi.org/10.1158/1078-0432.CCR-18-0323
Published: 14 September 2018
View article titled, Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Open the PDF for Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib in another window
Includes: Supplementary data
Journal Articles

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S. Pandha, Allan J. Pantuck, Anup Patel, Maria J. Lechuga, Alain Ravaud
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1554–1561.
https://doi.org/10.1158/1078-0432.CCR-17-2822
Published: 02 April 2018
View article titled, Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
Open the PDF for Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study in another window
Journal Articles

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5461–5471.
https://doi.org/10.1158/1078-0432.CCR-15-2839
Published: 14 November 2016
View article titled, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Open the PDF for Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes

Gabriel G. Malouf, Xiaoping Su, Hui Yao, Jianjun Gao, Liangwen Xiong, Qiuming He, Eva Compérat, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, Denaha J. Doss, Erika J. Thompson, David Khayat, Christopher G. Wood, Willie Yu, Bin T. Teh, John Weinstein, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 4129–4140.
https://doi.org/10.1158/1078-0432.CCR-13-3036
Published: 31 July 2014
View article titled, Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes
Open the PDF for Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes in another window
Includes: Supplementary data
Journal Articles

MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahira Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, Bernard Escudier
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3411–3421.
https://doi.org/10.1158/1078-0432.CCR-13-2173
Published: 30 June 2014
View article titled, MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Open the PDF for MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array in another window
Includes: Supplementary data
Journal Articles

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen-Chuan Ou, Daniel Castellano, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Sarah Beall, Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 3012–3022.
https://doi.org/10.1158/1078-0432.CCR-13-3006
Published: 29 May 2014
View article titled, Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Open the PDF for Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Heterogeneity of Translocation Renal Cell Carcinoma

Gabriel G. Malouf, Federico A. Monzon, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, Xiaoping Su, Hui Yao, Pheroze Tamboli, Dolores Lopez-Terrada, Maria Picken, Marileila Garcia, Asha S. Multani, Sen Pathak, Christopher G. Wood, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4673–4684.
https://doi.org/10.1158/1078-0432.CCR-12-3825
Published: 02 September 2013
View article titled, Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Open the PDF for Genomic Heterogeneity of Translocation Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Eric Angevin, Jose A. Lopez-Martin, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean-Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1257–1268.
https://doi.org/10.1158/1078-0432.CCR-12-2885
Published: 03 March 2013
View article titled, Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Open the PDF for Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussemart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druillennec, Stephan Vagner, Alain Eychène, Nicolas Dumaz, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 263–272.
https://doi.org/10.1158/1078-0432.CCR-11-1344
Published: 02 January 2012
View article titled, Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <em>HRAS</em>, <em>TP53</em>, and <em>TGFBR1</em>
Open the PDF for Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <em>HRAS</em>, <em>TP53</em>, and <em>TGFBR1</em> in another window
Includes: Supplementary data
Journal Articles

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

Judith Manola, Patrick Royston, Paul Elson, Jennifer Bacik McCormack, Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice Dutcher, Michael Atkins, Daniel Y.C. Heng, Toni K. Choueiri, Robert Motzer, Ronald Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5443–5450.
https://doi.org/10.1158/1078-0432.CCR-11-0553
Published: 14 August 2011
View article titled, Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
Open the PDF for Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group in another window
Includes: Supplementary data
Journal Articles

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4853–4863.
https://doi.org/10.1158/1078-0432.CCR-09-3343
Published: 29 September 2010
View article titled, Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Open the PDF for Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial in another window
Journal Articles

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6225–6231.
https://doi.org/10.1158/1078-0432.CCR-09-0068
Published: 30 September 2009
View article titled, A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Open the PDF for A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN

Emma R. Woodward, Christopher Ricketts, Pip Killick, Sophie Gad, M.R. Morris, Fred Kavalier, Shirley V. Hodgson, Sophie Giraud, Brigitte Bressac-de Paillerets, Cyril Chapman, Bernard Escudier, Farida Latif, Stéphane Richard, Eamonn R. Maher
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5925–5930.
https://doi.org/10.1158/1078-0432.CCR-08-0608
Published: 14 September 2008
View article titled, Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of <em>FLCN</em>
Open the PDF for Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of <em>FLCN</em> in another window
Journal Articles

Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer

Sylvie Négrier, David Perol, Alain Ravaud, Jacques O. Bay, Stéphane Oudard, Sylvie Chabaud, Pierre Fargeot, Remy Delva, Gael Deplanque, Gwenaelle Gravis, Bernard Escudier, for the French Immunotherapy Group
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5907–5912.
https://doi.org/10.1158/1078-0432.CCR-08-0236
Published: 14 September 2008
View article titled, Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer
Open the PDF for Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer in another window